[Fundamental and clinical studies of T-1982 (cefbuperazone) in the field of obstetrics and gynecology].
Human pharmacokinetics and clinical studies of T-1982 (cefbuperazone) were carried out and the following results were obtained. Transference into pelvic cavity fluid T-1982 level in pelvic cavity fluid showed the peak level of 48.0 micrograms/ml at 30 minutes after 2 hours drip infusion of 1 g in 1 case. The concentration tended to be more sustained than that of venous blood. Clinical study T-1982 was administered to 2 cases with pelveoperitonitis, 2 cases with puerperal fever and 1 case with adnexitis at a dose of 1 g twice a day for a period of 4 or 5 days. The clinical effect was excellent in 3 and good in 2 cases. Neither side effects nor abnormalities of laboratory findings were observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002513:Cephamycins / Q000378:metabolism* / Q000627:therapeutic use; D005122:Exudates and Transudates / Q000032:analysis; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D010388:Pelvis; D010538:Peritonitis / Q000188:drug therapy; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy
D002513:Cephamycins; C035978:cefbuperazone